Details of the Drug Combination

General Information of Drug Combination (ID: DCDOYAE)

Drug Combination Name

OSI-027 LY2523355

Indication

Disease Entry	Status	REF
Ewing sarcoma	Investigative	[1]

Component Drugs

OSI-027 DMJX3O8

LY2523355 DMCV602

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: TC-71

Zero Interaction Potency (ZIP) Score: 10.181

Bliss Independence Score: 9.907

Loewe Additivity Score: 2.157

LHighest Single Agent (HSA) Score: 5.14

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of OSI-027

Disease Entry	ICD 11	Status	REF
Renal cell carcinoma	2C90	Phase 2	[2]

OSI-027 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Serine/threonine-protein kinase mTOR (mTOR)	TTCJG29	MTOR_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

Indication(s) of LY2523355

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 2	[3]

LY2523355 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Kinesin-like protein KIF11 (KIF11)	TTTRP0H	KIF11_HUMAN	Modulator	[5]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2	Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011 Aug;10(8):1394-406.
3	ClinicalTrials.gov (NCT01416389) A Study of LY2523355 in Patients With Breast Cancer. U.S. National Institutes of Health.
4	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
5	Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39.